Back to today’s briefing

Story perspectives

Bristol Myers, Bain Capital Launch $300M Autoimmune Drug Venture

7/29/2025

50 6

Summary

Story summary

Bristol Myers Squibb and Bain Capital are teaming up to create a groundbreaking biopharmaceutical company dedicated to combating autoimmune diseases, fueled by a hefty $300 million investment. This venture aims to develop five innovative immunology drugs, targeting conditions like lupus and psoriasis. With Bristol Myers holding 20% equity, their partnership promises to amplify research and drive impactful treatments forward.

1 of 1

Story summary

Bristol Myers Squibb and Bain Capital are teaming up to create a groundbreaking biopharmaceutical company dedicated to combating autoimmune diseases, fueled by a hefty $300 million investment. This venture aims to develop five innovative immunology drugs, targeting conditions like lupus and psoriasis. With Bristol Myers holding 20% equity, their partnership promises to amplify research and drive impactful treatments forward.